USA flag logo/image

An Official Website of the United States Government

STTR Phase I: Novel Peptide Hydrogel for 3D Cell Culture

Award Information

National Science Foundation
Award ID:
Program Year/Program:
2013 / STTR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
1980 kimball ave Manhattan, KS 66506
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2013
Title: STTR Phase I: Novel Peptide Hydrogel for 3D Cell Culture
Agency: NSF
Contract: 1321261
Award Amount: $225,000.00


This Small Business Technology Transfer (STTR) Phase I project aims to use a newly discovered peptide (h9e) hydrogel technology to provide an affordable and easy-to-use 3D cell culture system with high throughput screen and accurate in vivo representative. To bridge the fundamental understanding of cellular characteristics and the extensive complexity of tissue and organs, hydrogel is the most promising material for 3D cell culture. Most of the existing hydrogel materials are limited under the physiological conditions, complex operating steps for cell encapsulation, difficulties for cell recovery from culture scaffold and high production cost. The objectives of this project are to 1) develop desirable h9e-medium hydrogel for cancer, normal and stem cell culture and 2) reduce hydrogel production cost. The success of this project will provide a superior 3D cell culture system with convenient cell encapsulation and recovery properties. Standard user-friendly protocols and successful examples of different cell lines growing in this system will be built. The optimal procedures of h9e chemical synthesis will be delivered for large scale synthesis with lower production cost. Furthermore, the proposed works will provide new insight about how drug discovery and tissue regenerative development be achieved based on an in vitro 3D cell culture system. The broader impact/commercial potential of this project, if successful, will be to provide an advanced life science tool for cell/tissue culture industry with over $6.0 billion global market. Simplification of operating process of 3D cell culture and reduction of hydrogel synthesis cost will greatly advance this technology to be used routinely for both academic and industry. Drug discovery and regenerative medicine development will be benefited from this high throughput screening and better in vivo representative cell culture system and extent to affect the pharmaceuticals, biotechnology and life sciences industries, which possess over $1,001.5 billion global market. Furthermore, the injectable capability of h9e hydrogel system will introduce many potential biomedical applications such as drug delivery, wounds healing, which are beyond the proposed 3D cell culture. The proposed approach will be broadly disseminated through international meetings, peer-reviewed journals, company website, and other outreach activities. Fundamental knowledge derived from this proposed technology will bridge the gap between cellular information and in vivo system and benefit all-level students, scientific community and entire society. The more accurate data derived from this tool will reduce the research use of animal models, which will relief the extensive criticism within our society.

Principal Investigator:

Hongzhou Huang
(785) 477-1913

Business Contact:

Hongzhou Huang
(785) 477-1913
Small Business Information at Submission:

1980 kimball ave Manhattan, KS 66506

EIN/Tax ID: 461365592
Number of Employees:
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Kansas State University
2 Fairchild Hall
Manhattan, KS 66505-
Contact: Xiuzhi Sun